US · Healthcare · Biotechnology
EPS came in at -3.20 against a street estimate of -3.68 — a beat of 13.0%.
Analysts rate Praxis Precision Medicines Inc a buy (11 buy, 0 hold, 1 sell out of 12) with an average price target of $610.05.
| Fund | Stake |
|---|---|
| HHG PLC | 12.41% |
| Orbis Allan Gray Ltd | 8.87% |
| BlackRock Inc | 8.34% |
| FMR Inc | 7.75% |
| Perceptive Advisors LLC | 7.30% |
| Baker Bros Advisors LP | 6.29% |
| Vanguard Capital Management, LLC | 4.38% |
| Deerfield Management Co | 3.46% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-07 |
| Current report · Q2 2026 | 2026-07-02 |
| Company announcement · Q2 2026 | 2026-06-29 |
| Company announcement · Q2 2026 | 2026-06-22 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-30 |
| Annual report FY2025 | 2026-02-19 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Praxis Precision Medicines Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.